Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. The company's lead compound, XPOVIO (selinexor), is approved in the U.S. in various hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. Its NEXPOVIO (selinexor) has also been granted conditional marketing authorization in combination with dexamethasone for adult patients with heavily pretreated multiple myeloma by the European Commission. In addition, the company's SINE compounds also show biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Further, it also has various investigational programs in clinical or preclinical development. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
IPO Year: 2013
Exchange: NASDAQ
Website: karyopharm.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/16/2025 | Buy → Neutral | H.C. Wainwright | |
| 7/11/2025 | $27.00 | Buy | H.C. Wainwright |
| 1/19/2023 | $8.00 | Overweight | Piper Sandler |
| 11/4/2022 | $7.00 → $10.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 3/8/2022 | $12.00 → $8.00 | Sector Perform | RBC Capital |
| 3/2/2022 | $8.00 → $6.00 | Market Perform | SVB Leerink |
| 2/9/2022 | $8.00 | Underweight → Neutral | JP Morgan |
| 1/10/2022 | $6.00 → $8.00 | Market Perform | SVB Leerink |
| 12/9/2021 | $8.00 → $9.00 | Sector Perform | RBC Capital |
| 11/19/2021 | $27.00 → $10.00 | Overweight → Equal-Weight | Morgan Stanley |
S-8 - Karyopharm Therapeutics Inc. (0001503802) (Filer)
10-Q - Karyopharm Therapeutics Inc. (0001503802) (Filer)
8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)
SCHEDULE 13G - Karyopharm Therapeutics Inc. (0001503802) (Subject)
8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)
8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)
10-Q - Karyopharm Therapeutics Inc. (0001503802) (Filer)
8-K - Karyopharm Therapeutics Inc. (0001503802) (Filer)
DEFA14A - Karyopharm Therapeutics Inc. (0001503802) (Filer)
DEF 14A - Karyopharm Therapeutics Inc. (0001503802) (Filer)
Fastest customizable press release news feed in the world
– New Patient Screening for Phase 3 SENTRY Trial in Myelofibrosis Expected to Close This Week; Top-Line Results Anticipated in March 2026 – – Total Revenue was $37.9 Million; U.S. XPOVIO® (selinexor) Net Product Revenue was $29.7 Million, up 6% compared to Second Quarter of 2024 – – Reaffirms Full-Year 2025 Total Revenue Guidance of $140 Million to $155 Million; Updates U.S. XPOVIO Net Product Revenue Guidance to $110 Million to $120 Million – – The Company is Exploring Financing Transactions and Strategic Alternatives to Extend its Cash Runway and Maximize Value – – Conference Call Scheduled for Today at 8:00 a.m. ET – NEWTON, Mass., Aug. 11, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc
-- Conference Call Scheduled for Monday, August 11, 2025, at 8:00 a.m. ET -- NEWTON, Mass., Aug. 5, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report second quarter 2025 financial results on Monday, August 11, 2025. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Monday, August 11, 2025, to discuss the financial results and other company updates. To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopha
NEWTON, Mass., Aug. 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 333 restricted stock units (RSUs) to one newly-hired employee. This RSU award was granted as of July 31, 2025 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as an inducement material to the new employee entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4). The RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive
NEWTON, Mass., July 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 666 restricted stock units (RSUs) to two newly-hired employees. These RSU awards were granted as of June 30, 2025 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4). Each RSU award
NEWTON, Mass., June 3, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team is scheduled to present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 3:10 p.m. ET in New York, NY. A live webcast of the presentation along with accompanying slides can be accessed under "Events & Presentations" in the Investor section of the Company's website, https://investors.karyopharm.com/events-presentations, and will be available for replay following the event. About Karyopharm Therapeutics Karyopharm Therapeutics Inc. (NASDAQ:KPTI) is
NEWTON, Mass., June 2, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 566 restricted stock units (RSUs) to two newly-hired employees. These RSU awards were granted as of May 31, 2025 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4). Each RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecuti
NEWTON, Mass., May 19, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the 2025 RBC Capital Markets Global Healthcare Conference in a fireside chat on Wednesday, May 21 at 10:00 a.m. ET in New York, NY. A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor section of the Company's website, https://investors.karyopharm.com/events-presentations, and will be available for replay following the event. About Karyopharm Therapeutics Karyopharm Therapeutics Inc. (NASDAQ:KPTI) is a comme
NEWTON, Mass., May 14, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced its abstract has been selected for a poster presentation at the 2025 European Hematology Association Annual Meeting (EHA) being held June 12-15 in Milan, Italy. The abstract contains data on selinexor monotherapy in a hard-to-treat, heavily pretreated myelofibrosis patient population from the Phase 2 XPORT-MF-035 trial. "We are encouraged by our new data in hard-to-treat myelofibrosis patients where we observed spleen volume reduction, symptom improvement, hemoglobin stabilization and evidence of disease modificat
– New Randomized Phase 2 Monotherapy Data from XPORT-MF-035 Trial in a Hard-to-Treat Patient Population Further Strengthens Conviction in Selinexor's Potential in Combination with Ruxolitinib in JAKi-Naïve Myelofibrosis in Ongoing Phase 3 SENTRY Trial – – Phase 3 SENTRY Trial Passed Planned Futility Analysis; Trial is Approximately 80% Enrolled with Target Enrollment Expected in June/July 2025 – – Demand for XPOVIO® (selinexor) Increased 5% in the First Quarter of 2025 Compared to the First Quarter of 2024; Total Revenue was $30.0 Million; U.S. XPOVIO® Net Product Revenue of $21.1 Million was Adversely Impacted by a $5.0 Million Increase in the Product Return Reserve due to Atypical Returns
-- Conference Call Scheduled for Monday, May 12, 2025, at 4:30 p.m. ET -- NEWTON, Mass., May 8, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report first quarter 2025 financial results on Monday, May 12, 2025. Karyopharm's management team will host a conference call and audio webcast at 4:30 p.m. ET on Monday, May 12, 2025, to discuss the financial results and other company updates. To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeu
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
4 - Karyopharm Therapeutics Inc. (0001503802) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
H.C. Wainwright downgraded Karyopharm Therapeutics from Buy to Neutral
H.C. Wainwright resumed coverage of Karyopharm Therapeutics with a rating of Buy and set a new price target of $27.00
Piper Sandler initiated coverage of Karyopharm Therapeutics with a rating of Overweight and set a new price target of $8.00
RBC Capital Mkts upgraded Karyopharm Therapeutics from Sector Perform to Outperform and set a new price target of $10.00 from $7.00 previously
RBC Capital reiterated coverage of Karyopharm Therapeutics with a rating of Sector Perform and set a new price target of $8.00 from $12.00 previously
SVB Leerink reiterated coverage of Karyopharm Therapeutics with a rating of Market Perform and set a new price target of $6.00 from $8.00 previously
JP Morgan upgraded Karyopharm Therapeutics from Underweight to Neutral and set a new price target of $8.00
SVB Leerink reiterated coverage of Karyopharm Therapeutics with a rating of Market Perform and set a new price target of $8.00 from $6.00 previously
RBC Capital reiterated coverage of Karyopharm Therapeutics with a rating of Sector Perform and set a new price target of $9.00 from $8.00 previously
Morgan Stanley downgraded Karyopharm Therapeutics from Overweight to Equal-Weight and set a new price target of $10.00 from $27.00 previously
This live feed shows all institutional transactions in real time.
SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)
SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)
SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)
SC 13G - Karyopharm Therapeutics Inc. (0001503802) (Subject)
SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)
SC 13G - Karyopharm Therapeutics Inc. (0001503802) (Subject)
SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)
SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)
SC 13G - Karyopharm Therapeutics Inc. (0001503802) (Subject)
SC 13G/A - Karyopharm Therapeutics Inc. (0001503802) (Subject)
Live finance-specific insights
– New Patient Screening for Phase 3 SENTRY Trial in Myelofibrosis Expected to Close This Week; Top-Line Results Anticipated in March 2026 – – Total Revenue was $37.9 Million; U.S. XPOVIO® (selinexor) Net Product Revenue was $29.7 Million, up 6% compared to Second Quarter of 2024 – – Reaffirms Full-Year 2025 Total Revenue Guidance of $140 Million to $155 Million; Updates U.S. XPOVIO Net Product Revenue Guidance to $110 Million to $120 Million – – The Company is Exploring Financing Transactions and Strategic Alternatives to Extend its Cash Runway and Maximize Value – – Conference Call Scheduled for Today at 8:00 a.m. ET – NEWTON, Mass., Aug. 11, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc
-- Conference Call Scheduled for Monday, August 11, 2025, at 8:00 a.m. ET -- NEWTON, Mass., Aug. 5, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report second quarter 2025 financial results on Monday, August 11, 2025. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Monday, August 11, 2025, to discuss the financial results and other company updates. To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopha
– New Randomized Phase 2 Monotherapy Data from XPORT-MF-035 Trial in a Hard-to-Treat Patient Population Further Strengthens Conviction in Selinexor's Potential in Combination with Ruxolitinib in JAKi-Naïve Myelofibrosis in Ongoing Phase 3 SENTRY Trial – – Phase 3 SENTRY Trial Passed Planned Futility Analysis; Trial is Approximately 80% Enrolled with Target Enrollment Expected in June/July 2025 – – Demand for XPOVIO® (selinexor) Increased 5% in the First Quarter of 2025 Compared to the First Quarter of 2024; Total Revenue was $30.0 Million; U.S. XPOVIO® Net Product Revenue of $21.1 Million was Adversely Impacted by a $5.0 Million Increase in the Product Return Reserve due to Atypical Returns
-- Conference Call Scheduled for Monday, May 12, 2025, at 4:30 p.m. ET -- NEWTON, Mass., May 8, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report first quarter 2025 financial results on Monday, May 12, 2025. Karyopharm's management team will host a conference call and audio webcast at 4:30 p.m. ET on Monday, May 12, 2025, to discuss the financial results and other company updates. To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask to be joined into the Karyopharm Therapeu
– Total Revenue of $145 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $113 Million for Full Year 2024 – – Top-Line Data Readout from Phase 3 SENTRY Trial Evaluating Selinexor in Combination with Ruxolitinib in Patients with JAKi-Naïve Myelofibrosis Anticipated in 2H 2025; Company on Track to Complete Enrollment in 1H 2025 – – Company Announces Update to Phase 3 XPORT-EC-042 Trial of Selinexor as Maintenance Therapy in Advanced or Recurrent TP53 Wild-Type Endometrial Cancer. Following Dialogue with the FDA Regarding the Evolving Treatment Landscape, Trial to Focus Enrollment on Patients with Either pMMR Tumors or Patients with dMMR Tumors that are Medically Ineligible for Checkp
-- Conference Call Scheduled for Wednesday, February 19, 2025, at 8:00 a.m. ET -- NEWTON, Mass., Feb. 12, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report fourth quarter and full year 2024 financial results on Wednesday, February 19, 2025. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Wednesday, February 19, 2025, to discuss the financial results and other company updates. To access the conference call, please dial (800) 836-8184 (local) or (646) 357-8785 (international) at least 10 minutes prior to the start time and ask
– Achieves Third Quarter 2024 Total Revenue of $38.8 Million and U.S. XPOVIO® (selinexor) Net Product Revenue of $29.5 Million; Continued Regulatory and Reimbursement Approvals Globally – – Following FDA Alignment, Absolute Change in Total Symptom Score (Abs-TSS) Will Replace TSS50 as a Co-Primary Endpoint in Phase 3 SENTRY Trial in JAKi Naïve Myelofibrosis (MF); Expected Top-line Data Read-out Remains on Track for 2H 2025 – – Narrows Full-Year 2024 Total Revenue Guidance Range to $145.0 Million to $155.0 Million; U.S. XPOVIO Net Product Revenue Guidance Range to $110.0 Million to $115.0 Million; R&D and SG&A Expense Guidance Range to $255.0 Million to $265.0 Million – NEWTON, Mass., Nov. 5,
-- Conference Call Scheduled for Tuesday, November 5, 2024, at 8:00 a.m. ET -- NEWTON, Mass., Oct. 31, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will report third quarter 2024 financial results on Tuesday, November 5, 2024. Karyopharm's management team will host a conference call and audio webcast at 8:00 a.m. ET on Tuesday, November 5, 2024, to discuss the financial results and other company updates. To access the conference call, please dial (800) 836-8184 (
Co-primary Endpoint Changed to Absolute Total Symptom Score (Abs-TSS) from Total Symptom Score Improvement of ≥ 50% (TSS50) Following Alignment with the FDA Spleen Volume Response Rate ≥ 35% (SVR35) Remains a Co-primary Endpoint Promising Improvement in Abs-TSS and SVR35 from Phase 1 Trial of Selinexor in Combination with Ruxolitinib Adds Confidence in Phase 3 SENTRY Trial Proactively Increasing Total Sample Size of the SENTRY Trial to Approximately 350 Patients to Further Increase the Statistical Powering; Expected Top-line Data Read-out Remains in 2H 2025 Company to Host a Conference Call Today at 8:00 a.m. ET Featuring Drs. Raajit Rampal and John Mascarenhas NEWTON, Mass., Oct. 31, 2024
Company to host a conference call tomorrow at 8:00 a.m. ET NEWTON, Mass., Oct. 30, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced it will host a conference call and audio webcast at 8:00 a.m. ET on Thursday, October 31, 2024 to provide a favorable study design update on the Company's pivotal Phase 3 SENTRY study in JAKi naive myelofibrosis. The call will feature leading myelofibrosis key opinion leaders Dr. Raajit Rampal, Director of the Center for Hematologic Maligna
Live Leadership Updates
NEWTON, Mass., Jan. 2, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Lori Macomber as Executive Vice President, Chief Financial Officer and Treasurer, effective January 3, 2025. In this role, Ms. Macomber will be responsible for leading and directing the financial activities of the Company. "Lori is an outstanding addition to the Karyopharm team," said Richard Paulson, President and Chief Executive Officer of Karyopharm. "She brings extensive experience in strategic financial management and operations, which will be critical as we execute on our strategy to grow
NEWTON, Mass., Dec. 9, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Brendan Strong as Senior Vice President of Investor Relations and Corporate Communications. "We are thrilled to have Brendan on board as we work towards delivering on and communicating important milestones for our organization in 2025," said Richard Paulson, President and Chief Executive Officer of Karyopharm. "Brendan's experience as a former sell-side analyst, advisor to biopharmaceutical companies and proven ability to develop strong investor relations and corporate communications programs wi
NEWTON, Mass., Nov. 20, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Kristin Abate, the Company's Vice President, Accounting, Corporate Controller and Assistant Treasurer has been appointed the Company's Vice President, Chief Accounting Officer, and Assistant Treasurer, effective November 20, 2024. Ms. Abate, who has also served as the Company's interim principal financial officer and interim principal accounting officer since November 6, 2024, has been designated as the Company's principal accounting officer, effective November 20, 2024. Ms. Abate will continue to serve as t
NEWTON, Mass., Sept. 1, 2023 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Zhen Su, MD, MBA, to its Board of Directors, effective August 31, 2023. Dr. Su is currently Chief Executive Officer and a member of the Board of Directors at Marengo Therapeutics, Inc., a company pioneering novel T-cell targeting therapeutics to fight cancer. "Dr. Su is a physician‐scientist and pharmaceutical industry leader who brings tremendous experience guiding products thro
DiaMedica Continues Building Out Board Of Directors With Key Biopharma Industry Leaders DiaMedica Therapeutics Inc. (NASDAQ:DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment of Tanya Lewis to its board of directors effective March 1, 2023. Ms. Lewis, a recognized leader in the biopharma industry, brings over 25 years of experience in drug development, having played a key role in the approval of multiple new drugs. Ms. Lewis currently serves as the Chief Development Operations Officer at Replimune Group, Inc. where she has oversight for development of an integrated clinica
- Formerly of Aravive, Genmab and Merck & Co., Dr. Rangwala will Lead Karyopharm's Clinical Development Programs and Strategy - - As Part of Karyopharm's Evolution, Co-Founders Dr. Shacham and Dr. Kauffman Will Transition Out of the Company on May 31, 2022 - - Dr. Shacham Will Continue her Engagement with the Company's Scientific Advisory Board and Serve in an Advisory Capacity - NEWTON, Mass., March 29, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Reshma Rangwala, MD, PhD, as the Company's Chief Medical Officer. Dr. Rangwala will join the Company in mid-April
– Elhan Webb, CFA, Formerly of Rubius Therapeutics and Radius Health, Appointed as Senior Vice President of Investor Relations – – Webb Brings More than 20 Years of Diverse International Experience Across Investor Relations, Business Development, Investment Analysis and Portfolio Management in the Healthcare and Biotechnology Fields – NEWTON, Mass., March 14, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Elhan Webb as Senior Vice President of Investor Relations. "Elhan brings tremendous experience with sell-side and buy-side analysts, as well as a robust networ
NEWTON, Mass., Feb. 22, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced changes to its clinical leadership team, including the appointment of Patricia Judson, M.D., as Senior Vice President of Medical Strategy and Stuart Poulton as Senior Vice President of Strategy and Portfolio Management. In addition, Jatin Shah, M.D. Executive Vice President and Chief Medical Officer has stepped down to pursue other professional opportunities, but will continue to serve Karyopharm in an advisory capacity. "As accomplished leaders with proven track records, Patricia and Stuart's expertise will be i
NEWTON, Mass., Dec. 6, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Peter K Honig, MD, MPH, to the Board of Directors, effective December 3, 2021. Dr. Honig brings to Karyopharm over 30 years of drug development and regulatory sciences experience from past leadership roles with Pfizer, Merck and the U.S. Food and Drug Administration (FDA). Dr. Honig replaces Mikael Dolsten, MD, PhD, who has transitioned off the Board due to competing professional demands, effective December 2, 2021. "We are honored to welcome Dr. Honig to our Board of Directors. His deep knowle
NEWTON, Mass., May 3, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended March 31, 2021. In addition, Karyopharm highlighted select corporate milestones, including details regarding the appointment of its next President and Chief Executive Officer, the ongoing U.S. commercialization of XPOVIO, and regulatory progress in Europe, and provided an overview of its key clinical development programs. "We are encouraged to see patient demand for XPOVIO return to growth in the first quarter of 2021, and we remain confident in its long-term commercial potent